|
Cizumab 100mg Bevacizumab
Bevacizumab, as it is generically called, is used for the treatment of metastatic colorectal cancer (mCRC). The product, which was launched under brand name Cizumab, has been approved by Drug Controller General of India (DCGI) and has been recommended as a first-line of treatment for mCRC. The product will be made available to patients in a single dose vial with two strengths.
Specifications :
|
